Vivos Therapeutics

Historical price data

Vivos Therapeutics is on a mission to redefine the standard of care for obstructive sleep apnea by addressing its underlying anatomical causes. The company has achieved FDA clearance for its Vivos CARE oral appliances for mild-to-severe OSA in adults and moderate-to-severe OSA in children, positioning it as a unique player in the sleep therapy market. Its strategy leverages a capital-light, provider-based distribution model focused on training dentists and integrating with the sleep medicine ecosystem. Vivos aims to transition patients from symptom management with CPAP to a finite therapeutic intervention with lasting physiological benefits.

A platform of FDA-cleared oral appliances (DNA, mRNA, mmRNA) designed to remodel craniofacial structure and expand the airway as a time-limited treatment for obstructive sleep apnea.

Vivos competes against CPAP giants (ResMed, Philips), traditional oral appliance makers (SomnoMed), and surgical options. Its differentiation hinges on positioning its technology as a time-limited, curative-intent treatment rather than a lifelong palliative device.